Skip to main content
Log in

CASE REPORT: Hepatic Injury Due to Troglitazone

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCES

  1. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 20(suppl 1):S5-S13, 1997

    Google Scholar 

  2. DeFronzo RA: The triumvirate: B-cell, muscle, liver: A collusion responsible for NIDDM. Diabetes 37:667-687, 1988

    PubMed  Google Scholar 

  3. Henry RR: Thiazolidinediones. Endocrin Metabol Clin North Am 26:553-573, 1997

    Google Scholar 

  4. Spencer CM, Markham A: Troglitazone. Drugs 54:89-101, 1997

    PubMed  Google Scholar 

  5. Inzucchi ES, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes. N Engl J Med 338:867-872, 1998

    PubMed  Google Scholar 

  6. Schwartz S, Raskin P, Fonseca V, Graveline JF: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 338:861-866, 1998

    PubMed  Google Scholar 

  7. Parke-Davis: Data on file. Morris Plains, New Jersey.

  8. Wise J: Diabetes drug withdrawn after reports of hepatic events. BMJ 315(7122):1564, 1997

    PubMed  Google Scholar 

  9. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM: Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 129:36-38, 1998

    PubMed  Google Scholar 

  10. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, Brunt EM: Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med 129:38-41, 1998

    PubMed  Google Scholar 

  11. Vella A, de Groen PC, Dinneen BF: Fatal hepatotoxicity associated with troglitazone. Ann Intern Med 129:1080, 1998 (letter)

    Google Scholar 

  12. Watkins PB, Whitcomb RW: Hepatic dysfunction associated with troglitazone. N Engl J Med 338:916-917, 1998 (letter)

    PubMed  Google Scholar 

  13. Misbin RI: Review of liver toxicity of troglitazone. Meeting of the Food and Drug Adminstration Cardiorenal Advisory Committee, January 21, 1998. Bethesda, Maryland

  14. Parke-Davis: Prescribing information for Rezulin. Morris Plains, New Jersey. July 1998

    Google Scholar 

  15. Zimmerman HJ, Ishak KG: Hepatic injury due to drugs and toxins. In Pathology of the Liver, 3rd ed. RNM MacSween, PP Anthony, PJ Scheuer, B Portmann, AD Burt (eds). Edinburgh, Churchill Livingstone, 1994

    Google Scholar 

  16. Farrell GC: Drug induced liver disease. Edinburgh, Churchill Livingstone, 1994

    Google Scholar 

  17. Lee WM: Drug induced hepatotoxicity. N Engl J Med 333:1118-1127, 1995

    PubMed  Google Scholar 

  18. Scheuer PJ, Lefkowitch JH: Liver Biopsy interpretation. London, WB Saunders, 1994

    Google Scholar 

  19. Patel JA, Miller E, Hu J, et al: BRL 49653 (a thiazolidiniedione) improves glycemic control in NIDDM patients. Diabetes 46:150A, 1997 (abstract 0578)

    Google Scholar 

  20. Patel JA, Miller E, Patwardhan R, et al: Rosiglitazone (BRL 49653) monotherapy has significant glucose lowering effect in type 2 diabetic patients. Proc 58th Annual Meeting of the ADA. Chicago, Illinois. June 13-16: A17, 1998 (abstract 0067)

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Malik, A.H., Prasad, P., Saboorian, M. et al. CASE REPORT: Hepatic Injury Due to Troglitazone. Dig Dis Sci 45, 210–214 (2000). https://doi.org/10.1023/A:1005450519498

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005450519498

Navigation